Puma Biotechnology price target raised to $29 from $26 at RBC Capital

RBC Capital analyst Kennen MacKay raised his price target on Puma Biotechnology to $29 after its release of a positive phase 3 NALA trial data which “could establish Nerlynx as Standard of Care in 3L+ metastatic HER2+ breast cancer on paper”. The analyst also keeps his Sector Perform rating on the shares, adding that the “commercial uptake” for the program remains a “concern” amid the changes in Standard of Care model to off-label therapies, which he says should keep the stock as a “show me” story.
https://thefly.com/landingPageNews.php?id=2838663